
-
Roivant NasdaqGS:ROIV Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
Location: 50 Broadway, London, SW1H 0DB, United Kingdom | Website: https://roivant.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.395B
Cash
4.887B
Avg Qtr Burn
-209.9M
Short % of Float
13.84%
Insider Ownership
29.44%
Institutional Own.
79.41%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTAMA (Tapinarof) Details Psoriasis | Approved Quarterly sales | |
VTAMA (Tapinarof) Details Atopic dermatitis | Approved Quarterly sales | |
Brepocitinib Details Dermatomyositis | Phase 3 Data readout | |
Batoclimab Details Eye disease , Thyroid Eye Disease | Phase 3 Data readout | |
Batoclimab Details Myasthenia gravis | Phase 3 Update | |
RVT-3101 Details Ulcerative colitis | Phase 3 Initiation | |
Brepocitinib Details Systemic lupus erythematosus, Chronic non-infectious uveitis, Dermatomyositis | Phase 3 Initiation | |
Mosliciguat Details Pulmonary hypertension associated with interstitial lung disease | Phase 2 Data readout | |
RVT-3101 Details Crohns disease | Phase 2 Data readout | |
Brepocitinib Details Sarcoidosis | Phase 2 Initiation | |
RVT-2001 Details Myelodysplastic syndrome | Failed Discontinued | |
Namilumab Details Sarcoidosis | Failed Discontinued |